Multiple Myeloma Experiences and Preferences: A Mixed Methods Study of Patients and Care Partners in the United States
MM patients and care partners played an active role in treatment decision-making. Collaborative discussions between clinicians, patients, and care partners are crucial for building trust and empowering patients. Reliable information and support resources including those for younger patients are essential for addressing the changing needs of patients and care partners. Understanding the evolving care journey is necessary to support patients with MM to optimize treatment success.
Authors
- Darcy R. Flora
- Patrick Hlavacek (ORCID: https://orcid.org/0000-0002-4752-3218)
- Rachel Byrd (ORCID: https://orcid.org/0009-0003-7339-3941)
- Erinn Hoag Goldman
- Thomas W. LeBlanc (ORCID: https://orcid.org/0000-0002-0546-7895)
- Joseph C. Cappelleri (ORCID: https://orcid.org/0000-0001-9586-0748)
- C Todd Kennedy
- Daniel Platt
Institutions
- Duke University (US)
- Pfizer (United States) (US)
- Unity Health System (US)
- Patient Advocate Foundation (US)
Publication Details
- Journal
- Patient Preference and Adherence
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/ppa.s491263
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Leukemia and Lymphoma Society
- Gilead Sciences
- Celgene
- Jazz Pharmaceuticals
- Agios Pharmaceuticals
- Adaptive Biotechnologies
- BeiGene
- Incyte
- Flatiron Health
- Seagen
- Astellas Pharma
- Servier
- National Institutes of Health
- Genentech
- National Institute of Nursing Research